Yes, laxatives can generally be used safely alongside GLP-1 medications like semaglutide and tirzepatide, but timing, type, and dosage require provider guidance
Tirzepatide (which activates both GLP-1 and GIP receptors) may cause slightly more appetite suppression initially, potentially requiring closer attention to protein intake
Insurance Acceptance We understand that managing healthcare costs is important
Ribas GS, Manfredini V, de Mari JF, Wayhs CY, Vanzin CS, Biancini GB, Sitta A, Deon M, Wajner M, Vargas CR (2010a) Reduction of lipid and protein damage in patients with disorders of propionate metabolism under treatment: a possible protective role of L-carnitine supplementation
It may be a good idea to call your insurance and ask for clarification
Abbreviations ASCVD: Atherosclerotic cardiovascular disease CHD: Coronary heart disease CI: Confidence interval CVD: Cardiovascular disease CVOT: Cardiovascular outcome trial DPP-4i: Dipeptidyl peptidase-4 inhibitor GLP-1: Glucagon-like peptide 1 GLP-1R: Glucagon-like peptide 1 receptor HbA1c: Glycated haemoglobin HR: Hazard ratio LDL: Low-density lipoprotein MACEs: Major cardiovascular events NO: Nitric oxide OR: Odds ratio PIONEER: Peptide Innovation for Early Diabetes Treatment ROS: Reactive oxygen species SC: Subcutaneous SNAC: Sodium N -[8-(2-hydroxybenzoyl)amino] caprylate TAGs: Triacylglycerols TGs: Triglycerides T2DM: Type 2 diabetes mellitus VLDL: Very-low-density lipoprotein References Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME
